Lung cancer is still the leading cause of cancer death worldwide.Non-small cell lung cancer(NSCLC)is the main pathological type of lung cancer,accounting for about 80％.Approximately 30％of all patients with NSCLC have resectable early and middle stage disease at the time of diagnosis.Recently,the epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)have made a major breakthrough in the adjuvant targeted therapy of EGFR-mutated resectable NSCLC,and are recommended by the guidelines for clinical use.In this review,we summarize the clinical research progress of perioperative adjuvant targeted therapy for EGFR-mutated resectable NSCLC,and discuss the key issues in the clinical re-searches.
维普
万方数据